Literature DB >> 19014910

Inhibition of topoisomerase II by 8-chloro-adenosine triphosphate induces DNA double-stranded breaks in 8-chloro-adenosine-exposed human myelocytic leukemia K562 cells.

Sheng-Yong Yang1, Xiu-Zhen Jia, Li-Yan Feng, Shu-Yan Li, Guo-Shun An, Ju-Hua Ni, Hong-Ti Jia.   

Abstract

8-Chloro-cAMP and 8-chloro-adenosine (8-Cl-Ado) are known to inhibit proliferation of cancer cells by converting 8-Cl-Ado into an ATP analog, 8-chloro-ATP (8-Cl-ATP). Because type II topoisomerases (Topo II) are ATP-dependent, we infer that 8-Cl-Ado exposure might interfere with Topo II activities and DNA metabolism in cells. We found that 8-Cl-Ado exposure inhibited Topo II-catalytic activities in K562 cells, as revealed by decreased relaxation of the supercoiled pUC19 DNA and inhibited decatenation of the kinetoplast DNA (kDNA). In vitro assays showed that 8-Cl-ATP, but not 8-Cl-Ado, could directly inhibit Topo IIalpha-catalyzed relaxation and decatenation of substrate DNA. Furthermore, 8-Cl-ATP inhibited Topo II-catalyzed ATP hydrolysis and increased salt-stabilized closed clamp. In addition, 8-Cl-Ado exposure decreased bromo-deoxyuridine (BrdU) incorporation into DNA and led to enhanced DNA double-stranded breaks (DSBs) and to increased formation of gamma-H2AX nuclear foci in exposed K562 cells. Together, 8-Cl-Ado/8-Cl-ATP can inhibit Topo II activities in cells, thereby inhibiting DNA synthesis and inducing DNA DSBs, which may contribute to 8-Cl-Ado-inhibited proliferation of cancers.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19014910     DOI: 10.1016/j.bcp.2008.10.022

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  8 in total

1.  Riccardin D, a novel macrocyclic bisbibenzyl, induces apoptosis of human leukemia cells by targeting DNA topoisomerase II.

Authors:  Xia Xue; Xian-Jun Qu; Zu-Hua Gao; Cui-Cui Sun; Hui-Ping Liu; Cui-Rong Zhao; Yan-Na Cheng; Hong-Xiang Lou
Journal:  Invest New Drugs       Date:  2010-10-06       Impact factor: 3.850

Review 2.  Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases.

Authors:  Lars Petter Jordheim; David Durantel; Fabien Zoulim; Charles Dumontet
Journal:  Nat Rev Drug Discov       Date:  2013-06       Impact factor: 84.694

3.  E2F1-mediated DNA damage is implicated in 8-Cl-adenosine-induced chromosome missegregation and apoptosis in human lung cancer H1299 cells.

Authors:  Yu-Ying Han; Zhe Zhou; Ji-Xiang Cao; Ya-Qiong Jin; Shu-Yan Li; Ju-Hua Ni; Guo-Shun An; Yu-Xiang Zhang; Hong-Ti Jia
Journal:  Mol Cell Biochem       Date:  2013-09-15       Impact factor: 3.396

4.  Purification of GidA protein, a novel topoisomerase II inhibitor produced by Streptomyces flavoviridis.

Authors:  Antony K Teresa Infanta S; S D Nisshanthini; M Palaniswamy; J Angayarkanni
Journal:  World J Microbiol Biotechnol       Date:  2013-08-31       Impact factor: 4.253

5.  Design, synthesis and evaluation of new marine alkaloid-derived pentacyclic structures with anti-tumoral potency.

Authors:  Sebastien Boucle; Celine Melin; Marc Clastre; Jerome Guillard
Journal:  Mar Drugs       Date:  2015-01-19       Impact factor: 5.118

Review 6.  Proposal of Dual Inhibitor Targeting ATPase Domains of Topoisomerase II and Heat Shock Protein 90.

Authors:  Kyu-Yeon Jun; Youngjoo Kwon
Journal:  Biomol Ther (Seoul)       Date:  2016-09-01       Impact factor: 4.634

7.  DNA Damage-Response Pathway Heterogeneity of Human Lung Cancer A549 and H1299 Cells Determines Sensitivity to 8-Chloro-Adenosine.

Authors:  Sheng-Yong Yang; Yi Li; Guo-Shun An; Ju-Hua Ni; Hong-Ti Jia; Shu-Yan Li
Journal:  Int J Mol Sci       Date:  2018-05-28       Impact factor: 5.923

8.  MsrB1 Promotes Proliferation and Invasion of Colorectal Cancer Cells via GSK-3β/β-catenin Signaling Axis.

Authors:  Xiao-Yu Chen; Sheng-Yong Yang; Xiao-Jie Ruan; Hong-Yue Ding; Ning-Xi Wang; Fang Liu; Jia-Chu Li; Yi Li
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.